Brind.
  1. Daiichi Sankyo and AstraZeneca are seeking approval for the Datroway antibody drug conjugate in the European Union, with the EMA opinion currently under review by the European Commission.

Daiichi Sankyo and AstraZeneca jointly conducted a Phase III trial of Enhertu for the treatment of NSCLC.

3 reports, 1 independent Updated Sep 11
Gone quiet Reached 2 outlets in its first 24 hours
Reports
3
Developments
1
Repetition
67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Daiichi Sankyo and AstraZeneca jointly conducted a Phase III trial of Enhertu for the treatment of NSCLC.

Who's involved

What this event is mainly about
Daiichi SankyoAstraZeneca

Keep exploring

Part of

Daiichi Sankyo and AstraZeneca are seeking approval for the Datroway antibody drug conjugate in the European Union, with the EMA opinion currently under review by the European Commission. All 1 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped
2 more outlets ran the same wire story